Atara Biotherapeutics FCF Yield

What does Atara Biotherapeutics do? Atara Biotherapeutics develops allogeneic T-cell therapies for severe diseases, targeting cancer, autoimmune, and viral conditions. The company's product candidates include ATA129 for Epstein-Barr virus-related diseases, ATA188 for multiple sclerosis, and ATA520 for cancers expressing WT1 antigen, currently in Phase I trials. ATA230, targeting cytomegalovirus, is in Phase II trials. Revenue comes from clinical development partnerships and potential future commercialization of these therapies. The firm focuses on third-party derived T-cell products, such as EBV-CTL, CMV-CTL, and WT1-CTL, which are developed for specific patient segments with life-threatening conditions. These therapies are designed to address unmet medical needs in oncology, neurology, and infectious disease markets. The company's pipeline is structured around clinical-stage therapeutics with potential for licensing or co-development agreements with pharmaceutical partners. Atara Biotherapeutics generates revenue through research and development collaborations, including potential milestone payments and royalties from partners who advance its therapies through clinical trials. The primary buyers of these partnerships are pharmaceutical companies seeking to expand their oncology and immunology portfolios. The company's target segments include patients with EBV-associated diseases, multiple sclerosis, and WT1-expressing cancers, as well as those with refractory CMV infections. Atara Biotherapeutics is one of the most popular companies on Eulerpool.